GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple ... Read More
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More